GSK catalysts
Catalysts and events linked to GSK, newest first.
DateCardAvg 5d
- 2026-09-28HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830GSK
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK HCM+0.14%
- 2026-09-28HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830GSK
- 2026-09-28HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830GSK HCM+0.14%
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK HCM+0.14%
- 2026-09-28HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR ConjugateGSK HCM+0.14%
- 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel PathwaysGSK RHHBY
- 2026-09-11GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent CliffGILD GSK
- 2026-09-11GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent CliffGILD GSK
- 2026-09-02Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10%GILD GSK
- 2026-09-02Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10%GILD GSK
- 2026-09-02Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10%GILD GSK
- 2026-09-02FDA approves Gilead's Bixlenvo as HIV franchise sales outlook raised to 9-10%GILD GSK
- 2026-08-07Global Influenza Vaccine Market Projected to Reach $13.3B by 2030GSK SNY
- 2026-08-07Global Influenza Vaccine Market Projected to Reach $13.3B by 2030GSK SNY
- 2026-06-25Global HPV Vaccine Market Projected to Reach $18.4B by 2034GSK MRK
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.